Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Rangering i aksjer #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Aksjekurs
$0.00204105
Markedsverdi
$138.92K
Endring (1 dag)
5.63%
Endring (1 år)
-60.44%
Land
GB
Handel Solvonis Therapeutics plc (SVNS)

Kategori

Pris SVNS pris med markedsverdi på B
Solvonis Therapeutics plc Solvonis Therapeutics plc
SVNS
$0.00204105
Markedsverdi av Solvonis Therapeutics plc(SVNS)
Markedsverdi: $138.92K
Per August 2026 har Solvonis Therapeutics plc en markedsverdi på $138.92K. Dette gjør Solvonis Therapeutics plc til det 40469th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Solvonis Therapeutics plc fra 2022 til 2026
SVNS sammenlignet med topp 5 mest populære stocks
Pris på SVNS Eiendel B Markedsverdi for B Resultater
Solvonis Therapeutics plc Solvonis Therapeutics plc
$80,358.71 $138.92K
$5.470T +3,937,121,289.65%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$65,630.42 $138.92K
$4.467T +3,215,518,705.67%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$61,330.28 $138.92K
$4.174T +3,004,836,235.16%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$54,361.71 $138.92K
$3.700T +2,663,415,733.27%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$41,936.14 $138.92K
$2.854T +2,054,633,061.29%